Shares of AstraZeneca PLC (LON:AZN - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the seven analysts that are currently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 1-year target price among brokerages that have covered the stock in the last year is GBX 7,542.80 ($97.40).
A number of equities analysts recently commented on AZN shares. JPMorgan Chase & Co. reissued an "overweight" rating on shares of AstraZeneca in a research note on Wednesday, February 19th. Shore Capital restated a "buy" rating on shares of AstraZeneca in a research note on Friday, March 7th. Finally, Berenberg Bank reaffirmed a "buy" rating and set a GBX 140 ($1.81) price objective on shares of AstraZeneca in a research report on Monday, January 27th.
Read Our Latest Stock Report on AZN
AstraZeneca Stock Down 1.3 %
Shares of LON:AZN traded down GBX 156 ($2.01) during trading hours on Friday, hitting £114.52 ($147.88). The company's stock had a trading volume of 1,003,695 shares, compared to its average volume of 24,690,625. The firm's fifty day moving average price is £115.32 and its 200 day moving average price is £113.21. AstraZeneca has a 52 week low of GBX 9,670 ($124.87) and a 52 week high of £133.88 ($172.88). The company has a market capitalization of £220.34 billion, a price-to-earnings ratio of 31.39, a P/E/G ratio of 0.86 and a beta of 0.17. The company has a debt-to-equity ratio of 73.83, a current ratio of 0.93 and a quick ratio of 0.59.
About AstraZeneca
(
Get Free ReportAstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Read More
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
